Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Buy
57
MNMD Quote, Financials, Valuation and Earnings
Last price:
$14.02
Seasonality move
:
315.15%
Day range:
$13.48 - $14.28
52-week range:
$4.70 - $14.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.03x
Volume:
2.2M
Avg. volume:
1.8M
1-year change:
98.02%
Market cap:
$1.3B
Revenue:
--
EPS (TTM):
-$1.97
Analysts' Opinion
-
Consensus RatingMind Medicine (MindMed), Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.73, Mind Medicine (MindMed), Inc. has an estimated upside of 93.44% from its current price of $14.02.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $14.02.
Fair Value
-
According to the consensus of 9 analysts, Mind Medicine (MindMed), Inc. has 93.44% upside to fair value with a price target of $25.73 per share.
MNMD vs. S&P 500
-
Over the past 5 trading days, Mind Medicine (MindMed), Inc. has overperformed the S&P 500 by 7.59% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Mind Medicine (MindMed), Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mind Medicine (MindMed), Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Mind Medicine (MindMed), Inc. reported revenues of --.
Earnings Growth
-
Mind Medicine (MindMed), Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Mind Medicine (MindMed), Inc. reported earnings per share of -$0.78.
Enterprise value:
1.1B
EV / Invested capital:
6.68x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-10.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-60.07%
Net Income Margin (TTM):
--
Return On Equity:
-80.63%
Return On Invested Capital:
-70.5%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3.2M | -$1.3M | -- | -- | -- | |
| Operating Income | -$85.6M | -$93.7M | -$151.2M | -$24.8M | -$45.7M | |
| EBITDA | -$82.3M | -$92.3M | -$151.2M | -$24.8M | -$45.7M | |
| Diluted EPS | -$1.99 | -$2.09 | -$1.97 | -$0.27 | -$0.78 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $146.5M | $156.5M | $120.1M | $299.4M | $215.8M | |
| Total Assets | $178.6M | $180.9M | $141.6M | $319.8M | $236.9M | |
| Current Liabilities | $5.8M | $26M | $31.2M | $33.3M | $65.4M | |
| Total Liabilities | $12.5M | $27.3M | $45.6M | $57.6M | $106.3M | |
| Total Equity | $166M | $153.6M | $96M | $262.2M | $130.6M | |
| Total Debt | -- | -- | $14.1M | $24.3M | $40.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$55.4M | -$73.4M | -$113.9M | -$17.2M | -$29.8M | |
| Cash From Investing | -- | -- | -$189.4M | -- | $16.3M | |
| Cash From Financing | $18.4M | $250.7M | $21.3M | $69.7M | $697.6K | |
| Free Cash Flow | -$55.4M | -$73.4M | -$113.9M | -$17.2M | -$29.8M | |
MNMD
Sector
Market Cap
$1.3B
$28.4M
Price % of 52-Week High
92.17%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-0.54%
-1.49%
1-Year Price Total Return
85.75%
-16.67%
Beta (5-Year)
2.792
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$12.70
200-day SMA
Buy
Level
$9.14
Bollinger Bands (100)
Buy
Level
9.85 - 12.67
Chaikin Money Flow
Sell
Level
-34.6M
20-day SMA
Buy
Level
$12.49
Relative Strength Index (RSI14)
Buy
Level
67.35
ADX Line
Buy
Level
22.75
Williams %R
Sell
Level
-17.1271
50-day SMA
Buy
Level
$12.30
MACD (12, 26)
Buy
Level
0.32
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
85.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1475)
Sell
CA Score
(Annual)
Level (-1.5186)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (2.6133)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, MNMD has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MNMD average analyst price target in the past 3 months is $25.73.
-
Where Will Mind Medicine (MindMed), Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mind Medicine (MindMed), Inc. share price will rise to $25.73 per share over the next 12 months.
-
What Do Analysts Say About Mind Medicine (MindMed), Inc.?
Analysts are divided on their view about Mind Medicine (MindMed), Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mind Medicine (MindMed), Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Mind Medicine (MindMed), Inc.'s Price Target?
The price target for Mind Medicine (MindMed), Inc. over the next 1-year time period is forecast to be $25.73 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MNMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mind Medicine (MindMed), Inc. is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MNMD?
You can purchase shares of Mind Medicine (MindMed), Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mind Medicine (MindMed), Inc. shares.
-
What Is The Mind Medicine (MindMed), Inc. Share Price Today?
Mind Medicine (MindMed), Inc. was last trading at $14.02 per share. This represents the most recent stock quote for Mind Medicine (MindMed), Inc.. Yesterday, Mind Medicine (MindMed), Inc. closed at $14.02 per share.
-
How To Buy Mind Medicine (MindMed), Inc. Stock Online?
In order to purchase Mind Medicine (MindMed), Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MNMD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MNMD
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
10.03x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
MNMD
Sector
Revenue growth
--
4.62%
Earnings growth
-185.11%
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.50
-$0.21
Profitability
MNMD
Sector
Profitability FY 2024
-$527K
$3.6M
Return on invested capital
-70.5%
-31.84%
Return on assets
-60.07%
-27.96%
Return on equity
-80.63%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
MNMD
Sector
Total cash
$209.1M
$26.4M
Short term investments
--
$25.7M
Total assets
$302.2M
$76.9M
Long term debt
$40.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 24
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 24
UniFirst Corp. [UNF] is up 0.77% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
